London scientists have created a “game-changing” new treatment for asthma attacks that can reduce the need for further treatment by 30 per cent. Benralizumab is the first treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years.

Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation.

King’s College, London researchers say they have found the first new treatment for asthma attacks in 50 years. Benralizumab injection dampens part of the immune system that can go into overdrive in flare-ups of both asthma and chronic obstructive pulmonary disease and can be used routinely.